Hand-foot skin reaction (HFSR), hypertension (HT), liver dysfunction checked by AST (aspartate aminotransferase) and ALT (alanine aminotransferase) values, hyperbilirubinemia as total bilirubin (T-BIL) increased, and thrombocytopenia as regorafenib-specific adverse events were selected for analyzing the relationship between measured cytokines levels at baseline and early phase of treatment start. This evidence concerns the gene GPT and Hyperbilirubinemia.